References
- Mylam KJ, El-Galaly TC Hutchings M, et al. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. Leuk Lymphoma 2014;55:1563–1569.
- Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.
- Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–1914.
- Meignan M, Gallamini A, Haioun C, et al. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260.
- Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging 2013;40:1312–1320.
- Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683–690.
- Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-Cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626–1632.
- Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527–533.
- Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.
- Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059–1066.
- Cheson BD, Fisher RI, Barrington E, et al. Recommendations for Initial evaluation, Staging and Response Assessment in Hodgkin and Non-Hodgkin Lymphoma – The Lugano Classification. J Clin Oncol 2014: sumitted.
- Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008;49:13–21.
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
- Juweid M, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 2005;23:4652–4661.
- Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol 2005;23:4577–4580.
- Fabel M, von Tengg-Kobligk H, Giesel FL, et al. Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV—a feasibility study. Eur Radiol 2008;18:1114–1122.
- Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?. Blood 2012;120:4913–4920.
- Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. Hematology Am Soc Hematol Educ Program 2012:322–327.